WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1891-01-01

Employees: 10K

Market Cap: -

Website: http://www.medschool.wustl.edu

Clinical Trials

Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients

Phase 1

Withdrawn

Conditions: Tumor, Brain
Anesthesia, Local

Interventions: Drug: Lidocaine
Drug: Sodium chloride
Drug: Bupivacaine

First Posted Date: 2017-06-06

Last Posted Date: 2020-10-22

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03177252

Scale Down for Endometrial Cancer

Not Applicable

Completed

Conditions: Cancer of the Endometrium
Endometrial Cancer

Interventions: Behavioral: ScaleDown
Behavioral: Enhanced Usual Care Packets
Other: 12-Item Short Form Health Survey
Other: International Physical Activity Questionnaire short form
Other: Multidimensional Body Self Relations Questionnaire - Appearance Subscales
Other: Cancer-Related Body Image Scale
Other: Patient Health Questionnaire 9-Item Version
Behavioral: iOTA

First Posted Date: 2017-05-30

Last Posted Date: 2019-02-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 155

Registration Number: NCT03169023

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Non Small Cell Lung Cancer
NSCLC
Non-small Cell Lung Cancer
Small Cell Lung Extensive Stage

Interventions: Drug: Pembrolizumab
Biological: NEO-PV-01 vaccine
Procedure: Biopsy
Drug: Poly ICLC
Procedure: Leukapheresis
Procedure: Peripheral blood samples

First Posted Date: 2017-05-25

Last Posted Date: 2019-04-12

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03166254

Impact of a Smartphone Application on Postpartum Weight Loss and Breastfeeding Rates Among Low-income, Urban Women

Not Applicable

Completed

Conditions: Breastfeeding

Interventions: Other: dummy app
Other: BreastFeeding Friend (BFF)

First Posted Date: 2017-05-25

Last Posted Date: 2021-07-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 170

Registration Number: NCT03167073

Locations: 🇺🇸
Center for Outpatient Health, Saint Louis, Missouri, United States

Effect of "Nicotinamide Mononucleotide" (NMN) on Cardiometabolic Function

Not Applicable

Completed

Conditions: Glucose Metabolism Disorders

Interventions: Other: Placebo
Dietary Supplement: NMN supplement

First Posted Date: 2017-05-12

Last Posted Date: 2021-07-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 25

Registration Number: NCT03151239

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Glenoid Bone Grafting for RTSA: Clinical & Radiographic Outcomes

Completed

Conditions: Osteo Arthritis Shoulders

First Posted Date: 2017-05-12

Last Posted Date: 2022-02-03

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 67

Registration Number: NCT03151109

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Reverse Shoulder Replacement: Age 60 or Younger Outcomes

Completed

Conditions: Shoulder Arthritis

First Posted Date: 2017-05-10

Last Posted Date: 2019-07-17

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 96

Registration Number: NCT03148184

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial

Not Applicable

Completed

Conditions: Thrombosis, LVAD
Anti-factor Xa
Left Sided Heart Failure
Anticoagulant Therapy
Left Ventricular Assist Device
aPTT
Gastro Intestinal Bleeding
Heparin

Interventions: Device: aPTT guided heparin management
Device: Anti-factor Xa guided heparin management

First Posted Date: 2017-05-08

Last Posted Date: 2020-02-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT03143569

Locations: 🇺🇸
Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States

Defining Predictors of RT Response to Vedolizumab in IBD

Phase 4

Active, not recruiting

Conditions: Crohn Disease of Small Intestine

Interventions: Drug: Vedolizumab 300 MG Injection [Entyvio]

First Posted Date: 2017-05-05

Last Posted Date: 2024-02-22

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 80

Registration Number: NCT03142321

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Phase 2

Completed

Conditions: Gastric Adenocarcinoma
Gastro-esophageal Junction Adenocarcinoma

Interventions: Drug: Irinotecan
Drug: Ramucirumab
Genetic: Blood for angiome profiling
Genetic: Blood for cfDNA

First Posted Date: 2017-05-04

Last Posted Date: 2024-06-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 40

Registration Number: NCT03141034

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy